- Revascularisation of complex patients in stable coronary artery disease
A predictor for 10-year mortality and clinical events in patients with chronic coronary total occlusion lesion
K Kim
- 10 years of clinical follow-up, MACCE occurs 6%, all-cause death in 18.5%, cardiac death in 9.9%, myocardial infarction (MI) 7.7%, revascularization in 30.7%, and stroke in 6.3% of patients
- A prior myocardial infarction, reduced LV ejection fraction, chronic kidney disease, and multi-vessel disease were associated with an increased risk of MACCE
- While the use of statins and aspirin reduced the risk of MACCE
- PCI for CTO lesions did not reduce the incidence of MACCE or all-cause death
- Partnering with patients through digital health
Quality of life after pulmonary veins isolation: outcomes from a digital follow-up program
R Teixeira
- No significant differences were seen according to baseline age and AF type
- During follow-up, AF recurred in 14.5% of patients, < 7% of patients had at least one emergency department visit and no deaths were reported
- Among patients with symptomatic AF, ablation led to significant improvements in QoL at 12 months
- Males in whom antiarrhythmic drugs were discontinued reported higher improvement in QoL
- Hypertension phenotypes and arterial stiffness
Arterial stiffness assessment in patients with resistant hypertension using pulse wave analysis
A Akhmimi
- The office and central BP readings were elevated in the resistant hypertension (RH) group compared to essential hypertension (CH) and normotensive (NC) (P<0.001)
- Aortic pulse pressure, MAP, and aortic augmentation pressure were significantly increased in patients with RH compared to other groups (P<0.001)
- Elevated AIx (Aortic augmentation index) was significantly and independently associated with the presence of RH
- Diabetes and stable coronary artery disease
Real-life use of novel glucose-lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes – experience from national use in the SWEDEHEART registry
V Ritsinger
- The use of novel glucose-lowering agents increased rapidly from 7% to 47% from 2016 year
- Use of SGLT2i increased from 4% to 38% and GLP-1 RA from 4% to 15%
- The cumulative event rate in all-cause death within 1 year occurred in 7% of patients with SGLT2i and/or GLP-1 RA compared to 4.5% in patients without new cardioprotective agents
- Increased awareness is needed to use effective cardioprotective treatment also in a high-risk population
-
Effect of initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy on ambulatory blood pressure indices
J Nolde
- At 12 weeks, mean 24-h ambulatory systolic and diastolic BP were 7 and 5.3 mmHg lower in the quadpill versus monotherapy group (p<0.001 for both)
- The reduction in systolic and diastolic ambulatory BP variability was more pronounced in the quadpill group at 12 weeks
- The rate of BP control at 12 weeks was higher in the quadpill group (p<0.001). These effects were maintained at 52 weeks.
- A quadruple quarter-dose combination compared to monotherapy resulted in greater ambulatory BP lowering across the entire 24-hour period with higher ambulatory BP control rates at both 12 and 52 weeks
-
Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: A systematic review and meta-analysis
DA Gorog
- Reduced DAPT intensity attenuated major bleeding (p=0.009) without impacting net adverse cardiovascular events (NACE) or major adverse cardiovascular events (MACE)
- In East Asians (EA), it reduced major bleeding (p=0.02) without affecting NACE or MACE
- Individualisation of DAPT strategy may be preferable to personalise care based on both ethnicity and prevailing risks
- Standard DAPT favours patients at high ischaemic risk, while shorter or less intense DAPT may benefit those at high bleeding risk
-
MINOCA in a young patient with antiphospholipid syndrome
M Bernardo
- Antiphospholipid syndrome can cause venous or arterial thrombosis and should be considered in young patients presenting with a myocardial infarction, as it might be the initial sign of the syndrome.
- In the presenting case of MINOCA, CMR was essential for diagnosis
- An ICD is recommended in patients with symptomatic HF and LVEF ≤35% despite ≥3 months of OMT
- Short and optimal duration of dual-antiplatelet therapy study after everolimus-eluting cobalt-chromium stent-3
STOPDAPT-3: An Aspirin-Free antithrombotic strategy for percutaneous coronary intervention
Natsuaki M
- Aspirin-free strategy using low-dose Prasugrel compared with DAPT failed to attest superiority for major bleeding within 1 month after PCI
- Aspirin used for limited period after PCI, DAPT exerted protective effect on coronary lesions regardless of the treatment
- No-aspirin group compared to DAPT was associated with excess of coronary events
- Functional versus Culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease
FIRE trial: Physiology-Guided Complete PCI in Older MI Patients
S Biscaglia
- Among patients aged ≥75 years with MI complete revascularization as compared to culprit-only revascularization strategy, reduced
- composite of death, MI, stroke, or ID revascularization
- Cardiovascular death or MI
- The safety endpoint in culprit-only reported 20.4% and for complete 22.5%
-
MI Trajectory- Subsequent cardiovascular disease trajectories following myocardial infarction
C Nathalie
- The study reported that cardiovascular diseases showed 47% mortality compared to lung diseases(20%) and infections (8%)
- Heart failure is the strongest predictor of mortality (more than MI)
- Important reductions in in-hospital mortality among patients with MI have translated in modest improvements in long-term survival
- Heart failure is the common consequence of MI
- Heart failure should be the focus for new preventive strategies after MI
